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The last 2–3 years have seen a series of exciting devel-
opments in the understanding of Angelman syndrome
(AS), beginning with identification of the disease gene
as a ubiquitin ligase gene (the first single-gene disorder
of the ubiquitination pathway) and the demonstration
of brain-specific imprinting for this gene. The imprinting
center (IC) that regulates expression of genes in this re-
gion has been delineated, and a mouse model of the
genetic defect has been characterized in detail, providing
the first evidence for a mammalian gene that is required
for long-term potentiation (LTP). AS is a neurologic dis-
order characterized by severe mental retardation, usually
with the failure to learn speech; seizures that are accom-
panied by electroencephalogram abnormalities; a move-
ment disorder, usually including gait ataxia and/or
tremor of the hands; unusual behavior, including happy
demeanor, frequent laughter, and easy excitability; de-
layed head growth with microcephaly by age 2 years;
and sleep disturbance (Williams et al. 1995). A summary
of earlier observations with detailed bibliography (Led-
better and Ballabio 1995) and more-recent reviews of
the molecular basis of AS are available (Lalande 1996;
Jiang et al. 1998b; Nicholls et al. 1998).
Figure 1 depicts significant features of the AS and
Prader-Willi syndrome (PWS) region of human chro-
mosome 15q11-q13. A common interstitial ∼4-Mb de-
letion in this region is found in both AS and PWS, but
the phenotypes in the two conditions are quite distinct,
as is their pattern of inheritance: deletions on the pa-
ternal chromosome cause PWS, whereas those on the
maternal chromosome cause AS. Consistent with this
unusual parental effect, many but not all of the genes
and transcripts from this region are subject to genomic
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imprinting. Thus, the SNRPN gene, encoding small nu-
clear ribonucleoprotein polypeptide N, is paternally ex-
pressed and maternally silenced in all tissues examined
and represents an important landmark within the region.
The SNRPN promoter is found within a CpG island
that is completely methylated on the maternal chro-
mosome and completely unmethylated on the paternal
chromosome. A bipartite imprinting center overlaps this
promoter; small deletions of the IC are implicated in
imprinting defects that can lead to AS or PWS. Other
notable loci in this region include the paternally ex-
pressed IPW, ZNF127, and NECDIN genes; the im-
printing of UBE3A is tissue-specific, with maternal
deficiency causing AS, and the imprinting status is
uncertain for a cluster of GABAA receptor genes. The
albinism locus (P) is not subject to genomic imprinting;
the HECR2 gene, which encodes a highly conserved gi-
ant protein, and MN7 map near the common PWS/AS
deletion breakpoints.
AS is estimated to occur in 1/15,000 births, and the
genetic basis for the disorder is unusually complex (table
1). A great majority of patients (65%–75%), designated
type Ia in table 1, carry de novo interstitial deletions of
maternal chromosome 15q11-q13. These deletions are
thought to occur through unequal crossing over between
complete or truncated copies of the HERC2 gene, which
form a set of low-copy repeats (Ji et al. 1999). The com-
mon deletion is readily diagnosed by use of FISH, and
its parental origin can be determined by methylation
analysis; in maternal deletions, characteristic of AS of
this type, the differentially methylated CpG island en-
compassing the promoter for SNRPN shows only the
paternal, unmethylated pattern. Recurrence risk for this
group of patients is extremely low. Closely related to
this common deletion is a group of very rare mutations
(!1%) including unbalanced translocations or inherited
interstitial deletions (type Ib in table 1). For example, a
Japanese family with an interstitial deletion that caused
AS when inherited maternally, but that yielded a normal
phenotype with no signs of Prader-Willi syndrome
(PWS) when inherited paternally, was extremely valua-
ble in distinguishing the critical regions for AS and PWS.
Approximately 3%–5% of patients with AS have pa-
ternal uniparental disomy (UPD) with maternal defi-
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Figure 1 The AS/PWS region of chromosome 15q11-q13 is depicted with various loci and expressed sequence tags indicated. The common
telomeric breakpoint and two centromeric breakpoints are depicted as vertical jagged lines and are separated by ∼4 Mb; distances are not to
scale. Most of the genes depicted also occur as a homologous region on mouse chromosome 7C, and the imprinted expression is generally
similar for mouse and human loci, where information is available. The IC is bipartite with the cis element of the IC required for maternal-to-
paternal switching (deletions in this region cause PWS) depicted as a blue oval overlapping the SNRPN promoter; the more upstream element
of the IC required for switching from paternal-to-maternal (deletions in this region cause AS) is depicted as a pink oval. Genes or transcripts
known to be paternally expressed are colored blue and indicated (pat), whereas the tissue-specific imprinting with maternal expression for
UBE3A is colored pink and indicated (mat). Transcripts that are known not to be imprinted or those for which imprinting is not certain are
shown in white.
ciency for 15q11-q13 and normal parental chromo-
somes (type IIa). Recurrence risk is low for UPD unless
a parental translocation (type IIb) predisposes the family
to recurrence. Approximately 7%–9% of patients with
AS have “imprinting” mutations, in which the maternal
chromosome has a paternal pattern of methylation and
imprinted gene expression for 15q11-q13. Among the
imprinting mutations, about half (type IIIa) are associ-
ated with small deletions that affect the more centrom-
eric portion of the bipartite IC near the SNRPN pro-
moter and that make the chromosome unable to switch
from the paternal to the maternal pattern of methylation
and expression; most cases of AS type IIIa are familial
(Ohta et al. 1999). Other cases that are identified as
imprinting mutations on the basis of methylation anal-
ysis are not associated with detectable deletions in the
IC (type IIIb). Familial recurrence has not been reported
for this group of patients, and the molecular mechanism
causing their defective imprinting mutation is unknown
(Buiting et al. 1998).
The UBE3A gene, which encodes E6-AP ubiquitin-
protein ligase (also known as ubiquitin ligase 3A) was
mapped to the AS critical region in 1994, but it was not
initially considered a strong candidate as an AS gene
because it did not appear to be imprinted. Subsequently,
however, point mutations in UBE3A, mostly truncating
mutations, were found in a significant but relatively
small fraction (4%–6%), of patients with AS (type IV).
Some of these mutations occurred de novo, but many
were inherited, and some families in this group include
a large number of affected individuals (Malzac et al.
1998; Fang et al. 1999). When large numbers of type
IIIa or type IV AS cases occur in an extended family, the
pattern of inheritance is distinctive, in that heterozygotes
are normal if the mutant chromosome is inherited from
the father but are affected if it is inherited from the
mother. The patients with point mutations in UBE3A
encoding E6-AP have relatively typical and complete AS
phenotypes (see Modifier Effects section, below).
A final group of patients (10%–14%) with a clinical
diagnosis of AS have no identifiable molecular abnor-
mality (type V). This group of patients likely represents
some combination of (1) as yet undetected lesions in
chromosome 15q11-q13 that affect the UBE3A locus;
(2) other novel genetic lesions that map elsewhere but
affect expression of UBE3A; and (3) incorrect diagnoses,
representing genocopies or phenocopies that do not per-
turb the expression of UBE3A. Because studies of pa-
tients with AS with normal methylation patterns have
identified UBE3A mutations much more often in mul-
tiplex families than in isolated cases, it is likely that many
patients with type V are erroneously diagnosed with AS
or that there is yet another molecular mechanism with
low recurrence risk to be identified. In most cases, AS
can be diagnosed and patients can be counseled ade-
quately by use of a combination of FISH, methylation
analysis, and DNA marker studies for UPD, but it is
labor intensive to search thoroughly for IC deletions
with imprinting mutations or for mutations in UBE3A.
Because only a small fraction of patients with a normal
methylation pattern have identifiableUBE3Amutations,
the frequency of patients with all laboratory studies
yielding normal results (type V) is significant, leaving
clinicians and families with uncertain diagnosis and re-
currence risk.
Modifier Effects
The P locus is not imprinted, but it falls within the
∼4-Mb common deletion region and modifies the phe-
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Table 1
Angelman Syndrome
Type Mechanism Proportion Methylationa Recurrence
Ia ∼4-Mb interstitial maternal del15q11-q13 65%–75% Abnormal Extremely low
Ib Unbalanced translocation or inherited interstitial deletion !1% Normal or abnormal Significant
IIa UPD maternal deficiency with normal parental chromosomes 3%–5% Abnormal Extremely low
IIb UPD with predisposing parental translocation !1% Abnormal Significant
IIIa Imprinting mutation with deletion of IC 3%–5% Abnormal Significant
IIIb Imprinting mutation without detectable deletion of IC 3%–5% Abnormal Low
IV Point mutations in UBE3A 4%–6% Normal Significant
V AS phenotype with no identifiable molecular abnormality 10%–14% Normal Occurs rarely
a “Abnormal” indicates that only the paternal, unmethylated pattern is seen on analysis of the SNRPN promoter region.
notype to include mild hypopigmentation in the type Ia
deletion form of AS. In humans or mice with loss-of-
function mutations on both alleles for the P or p loci,
respectively, the phenotype is albinism. The heterozygote
phenotype is more obvious in mice but is associated with
a mild decrease in pigmentation in humans. Hypopig-
mentation is not thought to be part of the phenotype
observed in type II, III, or IV AS, involving UPD, im-
printing mutations, or point mutations in UBE3A,
respectively.
Most type IV patients with AS have epilepsy, but some
reports suggest that epilepsy is more severe in patients
with type Ia who carry the ∼4-Mb deletion. The differ-
ence may be related to the presence of a cluster of
GABAA receptor genes located between UBE3A and the
P locus, as suggested by the finding that a knockout
mutation for one of these receptors (Gabrb3) causes ep-
ilepsy in mice (Delorey et al. 1998). The status of ge-
nomic imprinting regarding the GABAA cluster of re-
ceptors is uncertain (see bibliography in Jiang et al.
1998b), but maternal deficiency for GABRB3 may func-
tion as a modifier of the epilepsy phenotype, accounting
for the possibly greater severity in the deletion cases.
Thus, type IV AS is a single-gene disorder with point
mutations in UBE3A, but type Ia AS represents a con-
tiguous gene syndrome, in whichUBE3A, P, and perhaps
GABRB3 all contribute to the phenotype. Despite the
complexity of AS inheritance, the major phenotypic ef-
fects derive in all cases from deficient expression or func-
tion of the maternal UBE3A allele.
Brain-Specific Imprinting of UBE3A
Although imprinted expression was not found for
UBE3A in cultured human cells, once mutations causing
AS were found, it was quickly discovered that UBE3A
is imprinted in human brain and that the paternal allele
is silenced in that organ (Rougeulle et al. 1997; Vu and
Hoffman 1997). More-detailed in situ hybridization
data from the mouse indicates that Ube3a is preferen-
tially expressed from the maternal allele with silencing
of the paternal allele in Purkinje cells, hippocampal neu-
rons, and olfactory mitral cells, whereas expression is
not imprinted in most parts of the brain or in other
somatic tissues. This tissue specificity was first described
in UPD mice (Albrecht et al. 1997) and has been con-
firmed by use of a gene-targeting mutation (as described
below; also see Jiang et al. 1998a). The maternal defi-
ciency of Ube3a in Purkinje cells in mice could account
for the ataxia and tremor seen in patients with AS, and
the deficiency in the hippocampal neurons may explain
learning deficits and epilepsy, but the sublocalization of
tissue-specific imprinting in the brain has yet to be de-
termined in humans. As discussed below, indirect evi-
dence, based on excessive cytoplasmic p53 in the AS
brain, suggests that the gene is imprinted in human Pur-
kinje cells.
The molecular basis for the tissue-specific imprinting
is unknown but may be similar to the mechanisms used
at other imprinted loci or for X inactivation. UBE3A
uses multiple promoters and is subject to complex al-
ternative splicing of 5′ untranslated exons, and there is
precedent for alternative promoters involved in tissue-
specific imprinting of IGF2 (Vu and Hoffman 1994).
Molecular lesions that affect control elements separated
from the structural gene by as much as a megabase are
known to cause AS. One cis element that has been
mapped to a 1.15-kb region in the more centromeric
portion of the bipartite IC (Ohta et al. 1999) is required
for switching from paternal to maternal epigenotype.
There could well be tissue-specific enhancers or locus
control regions (Tanimoto et al. 1999) between the IC
and UBE3A or even flanking either of these sites. Also
potentially relevant to the mechanism of imprinting is
the report of an antisense transcript for the 3′ untran-
slated region of UBE3A (Rougeulle et al. 1998). Al-
though molecular lesions involving other putative cis-
acting elements may occur, it is the paternal silencing of
UBE3A that is tissue specific. Activation of maternal
expression is not involved, because the maternal allele
is expressed quite ubiquitously.
The Biochemistry of E6-AP, Encoded by UBE3A
The E6-AP protein, the product of the UBE3A gene,
was initially identified because of its ability to interact
4 Am. J. Hum. Genet. 65:1–6, 1999
with the E6 protein of human papillomavirus to promote
the ubiquitination and degradation of p53 (Huibregtse
et al. 1991). Ubiquitination (reviewed in Hershko and
Ciechanover 1998) involves four different classes of pro-
teins that act together to target selected proteins for deg-
radation. An E1 enzyme begins the process by forming
a high-energy thioester bond between a cysteine of its
active site and the C-terminal amino acid of ubiquitin.
Activated ubiquitin is then transferred to a series of E2
enzymes that also form thioester-linked complexes with
ubiquitin. Ubiquitin is then covalently attached to a pro-
tein substrate directly from an E2 enzyme or is trans-
ferred to a ubiquitin protein ligase (E3), which, in turn,
ubiquitinates the target protein. E3 proteins, including
E6-AP (Scheffner et al. 1993), provide specific recog-
nition of substrate proteins. E6-AP is the founding mem-
ber of the homologous to E6-AP C-terminal (hect) do-
main family of E3 proteins that now includes as many
as 20 different hect family proteins. Three other families
of E3 ligases have been described: E3 proteins designated
anaphase-promoting complex (APC) are implicated in
control of the cell cycle, as are members of the phos-
phoprotein-ubiquitin ligase family, referred to as the
Skp1-cullin-F box-protein (SCF) family. Another group
of E3s, the N-end rule family, recognize substrates based
on a characteristic N-terminal sequence (Hershko and
Ciechanover 1998). A final class of ubiquitination factor,
termed “E4” by Koegl et al. (1999), was recently shown
to allow target proteins to progress from the oligo-ubi-
quitinated state, which occurs by the action of hect do-
main-type E3 ligases, to multiubiquitination and pro-
teosomal degradation.
E6-AP can interact with and, presumably, accept ubi-
quitin from several E2 enzymes, including UbcH5,
UbcH6, UbcH7, and UbcH8. Subsequently, E6-AP ubi-
quitinates at least four proteins, but its targets might
easily number in the dozens or hundreds. In addition to
p53, the targets include HHR23A, a protein homolo-
gous to the yeast DNA repair factor RAD23; MCM-7,
a protein implicated in chromosomal replication; and
E6-AP itself. In addition to its ubiquitination activity,
E6-AP can also serve as a transcriptional coactivator for
steroid hormone receptors (Nawaz et al. 1999). Tran-
scriptional regulation and ubiquitination appear to be
independent activities, because an N-terminal domain
appears to mediate the former activity, whereas the ubi-
quitination domain is located at the C-terminal portion
of the protein.
Mouse Models of Angelman Syndrome
Mice with paternal UPD for chromosome 7 were first
reported as a model for AS (Cattanach et al. 1997),
although a previously known radiation-induced deletion
(p30Ub; Johnson et al. 1995) that lacks both the p locus
and Ube3a could also be used to produce maternal de-
ficiency for Ube3a. Both of these models involve large
regions of mouse chromosome 7C and could affect mul-
tiple loci. We produced a null mutation in Ube3a by
using gene targeting and found that maternal deficiency
mice show no detectable expression of the locus in hip-
pocampal neurons or in cerebellar Purkinje cells (Jiang
et al. 1998a). The maternal deficiency (AS) mice dem-
onstrate motor dysfunction, inducible seizures, and a
defect in contextual learning and hippocampal LTP.
Contextual fear conditioning is an associative learning
behavior implicated in rat brain–lesion studies to involve
hippocampal function. LTP is an electrophysiological
phenomenon whereby stimulation of presynaptic axons
increases the strength of connections to postsynaptic
neurons for days to weeks and is widely regarded as a
form of neuronal plasticity that is relevant to learning
and memory. LTP is generally considered the strongest
candidate cellular mechanism for learning and memory
(see Meiri et al. 1998 for a dissenting view; Stevens
1998). The defect in LTP, which is quite prominent in
AS mice, represents the first evidence for a role of ubi-
quitination in mammalian LTP. In Aplysia, a much-stud-
ied model system for the molecular basis of associative
learning, ubiquitin-dependent proteolysis is implicated
in the synaptic changes that occur in long-term facili-
tation. Nevertheless, it is uncertain whether E6-AP plays
a direct or indirect role in affecting LTP. Because the
mice have normal neuroanatomy and normal baseline
synaptic transmission (Jiang et al. 1998a), the defect in
LTP may represent a primary abnormality. AS mice have
an increased abundance of cytoplasmic p53 in Purkinje
cells and some hippocampal neurons, which suggests
that E6-AP regulates the abundance of p53 directly in
vivo through ubiquitination.
Pathogenesis of Angelman Syndrome
Despite the flood of recent data on UBE3A expression
and E6-AP biochemistry, the mechanisms whereby ma-
ternal deficiency of E6-AP causes the phenotypic features
of AS remain largely unknown. Significant Purkinje cell
and granule cell loss and increased abundance of p53 in
Purkinje cells were found at autopsy in a 21-year-old
patient with a clinical diagnosis of AS (Jay et al. 1991;
Jiang et al. 1998a). However, normal neuropathology
has been reported in a 3-year-old patient (Kyriakidas et
al. 1992), which suggests that Purkinje cell death is, at
most, a late effect of maternal deficiency for UBE3A.
Moreover, the neuroanatomy in AS mice up to 3–4 mo
of age is also normal, despite their phenotypic abnor-
malities. The elevated cytoplasmic levels of p53 in hu-
man Purkinje cells in AS suggest that expression of
UBE3A is imprinted in this cell type in humans, as it is
in mice. This high level of p53 might initiate apoptosis
and contribute to cell loss at later ages. Candidate pro-
teins in Purkinje cells and proteins implicated in LTP in
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the hippocampus can be evaluated as potential targets
for ubiquitination by E6-AP. Ube3a mutant mice should
provide an additional means to identify target proteins
that are found in Purkinje cells or hippocampal neurons
at elevated levels relative to wild type. Finally, the tran-
scriptional coactivation capacity of E6-AP must be con-
sidered, along with ubiquitination, as possibly contrib-
uting to the pathogenesis. However, the finding that AS
can arise from missense mutations in the ubiquitination
domain may argue that ubiquitination defects per se are
sufficient to cause the disease. The transcriptional func-
tion of some of these mutant E6-AP proteins appears to
be preserved in tissue culture studies (Nawaz et al.
1999).
Potential for Additional Disorders of Ubiquitination
and LTP
AS represents the first clear example of a single-gene
disorder involving the ubiquitination pathway in hu-
mans, although numerous such defects have been de-
scribed in yeast and Drosophila (see Jiang et al. 1998a
and references therein). In mice, the disruption of an E2
locus, UbcM4, leads to embryonic lethality (Harbers et
al. 1996), and a mutation in an E3 ubiquitin-protein
ligase, encoded by the Itch locus, causes a complex spec-
trum of immunologic and inflammatory abnormalities
(Perry et al. 1998). The velocardiofacial/DiGeorge syn-
drome may be caused by a defect in a protein involved
in degradation of ubiquitinated proteins (Yamagishi et
al. 1999). Given the large number of E2 and E3 loci in
mammals, it is likely that additional single-gene disor-
ders involving the ubiquitination pathway will be iden-
tified in humans. In addition, abnormalities of ubiqui-
tination are likely to be secondarily involved in many
pathological conditions, and they are already implicated
in neurodegenerative triple-repeat disorders (Cummings
et al. 1998; Chai et al. 1999), Alzheimer disease, and
other neurodegenerative disorders (Alves-Rodrigues et
al. 1998).
There is little precedent for the effects of abnormalities
of LTP on human learning and behavior. Since mice with
AS have an abnormality of LTP, it is of particular interest
to carefully examine the cognitive features of human
patients with AS. It is likely that additional instances
will arise in which mice and humans carry mutations in
orthologous genes and a defect in LTP will be shown in
the mouse. Such models hold the promise of a deeper
understanding of the relationships between the cellular
events of LTP and the behavioral changes we observe as
learning and memory in mice and humans.
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